To evaluate the efficacy of citicoline eye drops 2% in reducing visual field deterioration in patients with progressing OAG treated according to best clinical practice. Secondary objectives are assessing the effect of citicoline eye drops 2% on changes in structural parameters measured by Spectral Domain Optical Coherence Tomography (SD-OCT) and evaluating the safety of citicoline eye drops 2%
Signed written informed consent.
Age ≥ 18 years.
Eyes with OAG, Pseudoexfoliation and pigmentary glaucoma will be included.
Best Corrected Visual Acuity (BCVA) ≥ 0.5 for the study eye.
Cataract in the study eye which, in the opinion of the clinician, may require cataract surgery within the next three years.
Only-eye patients (visual acuity < 0.1 decimals in one eye or more than two paracentral VF locations with a sensitivity of < 10 dB).
Known intolerance or allergy to any of the components in the eye drops.
Diode laser treatment or glaucoma surgery in the past 2 years or cataract surgery within the last 6 months in the study eye.
Omikron Italia S.r.l.
Lead sponsor
OPIS Spain
Collaborator